Latest Industry Projects

Chugai Pharmaceutical plans to build new Antibody API Manufacturing plant at Ukima Plant, Tokyo

Chugai Pharmaceutical plans to build new Antibody API Manufacturing plant at Ukima Plant, Tokyo

Introduction:

Chugai Pharmaceutical announced plans to construct a new plant for manufacturing antibody active pharmaceutical ingredients (API) at the Ukima Plant (Kita-ku, Tokyo) of Chugai Pharma Manufacturing Co., Ltd., a manufacturing subsidiary of the company.

Features:

This new plant for manufacturing antibody active pharmaceutical ingredients (API) capable of high-mix low-volume production for late-stage investigational drugs and initial commercial products at the Ukima Plant. Chugai is aiming to possess global top-class competitiveness by minimizing the time required from the development to launch of a new drug by handling the simultaneous development of multiple products.

With this capital investment, six 6,000 L bioreactor tanks will be newly installed. Combined with the existing two 2,500 L tanks and four 2,000 L tanks, the Ukima Plant will have a total capacity of 49,000 L bioreactor tanks, with a consistent system from process development to production of antibody API of investigational drugs in late-stage clinical studies and initial commercial products at one site.

Overview of Construction Plan of Antibody API Production Plant at Ukima Plant

  • • Start of Construction: January 2016
  • • Completion of Construction: December, 2017
  • • Total Investment: 37.2 billion yen
  • • Completion of Building: July, 2018
  • • Start of Operation: June, 2019
  • • Total Floor Area: 26,634 m2

     

Specifications:

Company Name Chugai Pharmaceutical
Location  Tokyo
Type New Manufacturing Plant
Construction Area 4,066 m2

 

chugai-pharm.co.jp

Other Projects